Integrity Alliance LLC. Purchases New Position in Edwards Lifesciences Corporation $EW

Integrity Alliance LLC. purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 3,168 shares of the medical research company’s stock, valued at approximately $230,000.

Several other hedge funds have also added to or reduced their stakes in EW. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $266,000. Bank Pictet & Cie Europe AG boosted its position in Edwards Lifesciences by 16.7% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company’s stock worth $757,000 after buying an additional 1,463 shares during the period. Gotham Asset Management LLC boosted its position in Edwards Lifesciences by 105.8% during the 4th quarter. Gotham Asset Management LLC now owns 16,423 shares of the medical research company’s stock worth $1,216,000 after buying an additional 8,444 shares during the period. ProShare Advisors LLC boosted its position in Edwards Lifesciences by 10.3% during the 4th quarter. ProShare Advisors LLC now owns 90,668 shares of the medical research company’s stock worth $6,712,000 after buying an additional 8,491 shares during the period. Finally, Rafferty Asset Management LLC lifted its position in shares of Edwards Lifesciences by 9.5% in the 4th quarter. Rafferty Asset Management LLC now owns 66,887 shares of the medical research company’s stock worth $4,952,000 after purchasing an additional 5,788 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,014 shares of company stock valued at $1,698,844. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $77.50 on Friday. The firm has a market capitalization of $45.50 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. The firm has a fifty day simple moving average of $78.92 and a two-hundred day simple moving average of $75.42. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the business posted $0.70 EPS. Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on EW shares. Stifel Nicolaus boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Thursday, July 10th. Evercore ISI boosted their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a research report on Friday, July 25th. Finally, Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $86.26.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.